

MOL #115626

Title:

Chemically Modified Derivatives of the Activator Compound Cloxyquin Exert Inhibitory Effect on TRESK (K_{2P18.1}) Background Potassium Channel

Author information: Miklós Lengyel¹, Ferenc Erdélyi², Enikő Pergel¹, Ágnes Bálint-Polonka^{3,*}, Alice Dobolyi¹, Péter Bozsaki¹, Mária Dux⁴, Kornél Király⁵, Tamás Hegedűs⁶, Gábor Czirják¹, Péter Mátyus^{3,**} and Péter Enyedi¹

From the Department of Physiology, Faculty of Medicine, Semmelweis University, Budapest, Hungary

Affiliations:

1: Department of Physiology, Faculty of Medicine, Semmelweis University, Budapest, Hungary

2: Gene Technology Division, Institute of Experimental Medicine – HAS, H-1083 Budapest, Hungary

3: Department of Organic Chemistry, Faculty of Pharmacy, Semmelweis University

4: Department of Physiology, Faculty of Medicine, University of Szeged, Szeged, Hungary

5: Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University

6: Department of Biophysics and Radiation Biology, Faculty of Medicine, Semmelweis University

*: Present address: Hungarian Accreditation Committee, 1013 Budapest, Krisztina krt. 39

** : Present address: Faculty of Health and Public Services, Semmelweis University

MOL #115626

Running title: Inhibition of TRESK by cloxyquin derivatives

Correspondence should be addressed to Péter Enyedi, Department of Physiology, Semmelweis University, P.O. Box 2, H-1428 Budapest, Hungary; E-mail: enyedi.peter@med.semmelweis-univ.hu; Tel.: +36 1 459 1500/60431; fax: +36 1 266 7480.

Pages: 37

Tables: 0

Figures: 8

References: 30

Word count:

Abstract: 250

Introduction: 426

Discussion: 1472

Abbreviations:

DRG: Dorsal root ganglion; RR: Ruthenium red; TWIK: Tandem of Pore Domains in a Weak Inward Rectifying K⁺ channel; TREK: TWIK-Related K⁺ channel; TASK: TWIK-Related Acid-Sensitive K⁺ channel; TALK: TWIK-Related Alkaline pH-Activated K⁺ channel; THIK: Tandem Pore Domain Halothane-Inhibited K⁺ channel; TRESK: TWIK-Related Spinal Cord K⁺ channel

MOL #115626

Abstract

Cloxyquin has been reported as a specific activator of TRESK (K_{2P}18.1, TWIK-related spinal cord K⁺ channel) background potassium channel. In this study, we have synthesized chemically modified analogues of cloxyquin and tested their effects on TRESK and other K_{2P} channels. The currents of murine K_{2P} channels, expressed heterologously in *Xenopus* oocytes, were measured by two-electrode voltage clamp, whereas the native background K⁺ conductance of mouse dorsal root ganglion (DRG) neurons was examined by the whole-cell patch clamp method. Some of the analogues retained the activator character of the parent compound, but more interestingly, other derivatives inhibited mouse TRESK current. The inhibitor analogues (A2764 and A2793) exerted state-dependent effect. The degree of inhibition by 100 μM A2764 (77.8±3.5%, n=6) was larger in the activated state of TRESK (i.e. after calcineurin-dependent stimulation) than in the resting state of the channel (42.8±11.5% inhibition, n=7). The selectivity of the inhibitor compounds was tested on several K_{2P} channels. A2793 inhibited TASK-1 (100 μM, 53.4±13.5%, n=5), while A2764 was more selective for TRESK, it only moderately influenced TREK-1 and TALK-1. The effect of A2764 was also examined on the background K⁺ currents of DRG neurons. A subpopulation of DRG neurons, prepared from wild-type animals, expressed background K⁺ currents sensitive to A2764, while the inhibitor did not affect the currents in the DRG neurons of TRESK-deficient mice. Accordingly, A2764 may prove to be useful for the identification of TRESK current in native cells, and for the investigation of the role of the channel in nociception and migraine.

MOL #115626

Introduction

Background (leak) potassium currents are responsible for the generation of the resting membrane potential and also play an important role in the adjustment of cellular excitability. The molecular correlates of the background potassium currents are the two-pore domain potassium channels (K_{2P}). To date, 15 K_{2P} subunits have been identified in mammalian cells. These channels are regulated by a large variety of physicochemical factors, intracellular signaling pathways and drugs (for review, see (Enyedi and Czirjak, 2010)) .

TRESK (TWIK-related spinal cord K^+ channel, also known as $K_{2P18.1}$) was first cloned from human spinal cord (Sano et al., 2003). TRESK is activated by the cytoplasmic Ca^{2+} signal, via the calcium/calmodulin-dependent phosphatase, calcineurin (Czirjak et al., 2004). TRESK is abundantly expressed in the primary sensory neurons of the dorsal root (Yoo et al., 2009) and trigeminal ganglia (Bautista et al., 2008; Yamamoto et al., 2009). Single channel studies indicated that TRESK provides a major component of the background potassium current in rat dorsal root ganglion (DRG) neurons (Kang and Kim, 2006). It is a plausible hypothesis that TRESK modulates the activity of sensory neurons and the absence of TRESK current results in an increased excitability leading to disorders in nociception. A decrease of TRESK expression has been reported in a model of neuropathic pain (Tulleuda et al., 2011). In further support of this hypothesis, a mutation of TRESK leading to a non-functional channel fragment with dominant negative effect has been recognized in a cohort of patients suffering from migraine (Lafreniere et al., 2010).

In order to understand the role of TRESK in physiological and pathophysiological nociception, appropriate pharmacological tools are necessary for selective modulation of the channel. However, pharmacological targeting of TRESK and other K_{2P} channels is a difficult task (for a recent review on the pharmacology of TRESK, see (Enyedi and Czirjak, 2015)).

MOL #115626

The anti-amoebic drug cloxyquin was identified as an activator of TRESK (Wright et al., 2013). We have recently reported that cloxyquin is a selective activator of TRESK in the K_{2P} family. The stimulatory effect of cloxyquin was independent on the Ca^{2+} /calcineurin pathway, suggesting that cloxyquin is a direct activator of the channel. We have also shown that cloxyquin activates TRESK in isolated mouse DRG neurons (Lengyel et al., 2017). In the present study, we have produced 28 chemically modified analogues of cloxyquin and examined their effects on TRESK channels. Some of these derivatives activated TRESK with similar efficiency and potency as the parent compound. On the other hand, we obtained several compounds suitable for the selective inhibition of TRESK current in an activation-state dependent manner.

MOL #115626

Methods

Plasmids, cRNA synthesis

The cloning of mouse TASK-1/2/3, TREK-2, TALK-1, THIK-1 and TRESK has been described previously (Czirjak and Enyedi, 2006; Czirjak et al., 2004). The plasmids coding mouse TREK-1 and TRAAK channels were kindly provided by Professor M. Lazdunski and Dr. F. Lesage. The plasmids were linearized and used for *in vitro* cRNA synthesis using the Ambion mMESSAGE mMACHINE™ T7 *in vitro* transcription kit (Ambion, Austin, TX). The structural integrity of the RNA was checked on denaturing agarose gels.

Animal husbandry, preparation and microinjection of Xenopus oocytes. Generation of a TRESK knockout mouse line. Isolation of dorsal root ganglion neurons.

Xenopus laevis oocytes were prepared as previously described (Czirjak and Enyedi, 2002). For the expression of the different channels, the oocytes were injected with 57 pg - 4 ng of cRNA (depending on the channel type) one day after defolliculation. Injection was performed with a Nanoliter Injector (World Precision Instruments, Sarasota, FL). *Xenopus laevis* frogs were housed in 50 L tanks with continuous filtering and water circulation. Room temperature was 19 °C. Frogs were anesthetized with 0.1 % tricaine solution and killed by decerebration and pithing.

FVB/Ant (**FVB.129P2-Pde6b+Tyrc-ch/Ant**) mice were obtained from the Institute of Experimental Medicine of the Hungarian Academy of Sciences (Budapest, Hungary). TRESK knock-out animals were generated by the Transcription Activator-Like Effector Nuclease (TALEN) technique using plasmids ordered from Addgene (TALE Toolbox Kit # 1000000019 deposited by Feng Zhang). Mouse TRESK specific TALEN recognition sites were designed for the genomic sequence of the first exon (corresponding to the N-terminal intracellular domain of the channel)

MOL #115626

using the 5`-TN¹⁹ N¹⁴⁻²⁰ N¹⁹A-3` formula, with the following sequences: left TALEN recognition site: 5`tgaggagccacctgaggcca, right TALEN recognition site: 5`ccctggggaaggccagggga, and an 18 bp (5`ggagatgctgtcctgagg) FokI nuclease dimerization and cutting sequence in between. Mouse TRESK recognizing TALEN plasmids were assembled according to the protocol of Sanjana et al. (Sanjana et al., 2012). TALEN mRNAs were produced using the Ambion mMACHINE mMACHINE™ T7 *in vitro* transcription kit (Ambion, Austin, TX). TALEN mRNAs were microinjected at a concentration of 20-20 ng/μl into the pronuclei of fertilized eggs of FVB/Ant mice. Pups were analyzed with Surveyor assay plus sequencing. In twelve mice, among the 61 born pups the TRESK (KCNK18) gene was changed and a founder bearing a 33 bp deletion and also a mutation introducing a stop codon was chosen to establish a colony.

Adult female wild-type and TRESK knockout (TRESK KO) mice (of 2-3 months age) were used for the patch clamp experiments in this study. The animals were maintained on a 12 hour light/dark cycle with free access to food and water in a SPF animal facility. Mice were killed humanely by CO₂ exposure (CO₂ was applied until death of the animals). DRGs were dissected from the thoracic and lumbar levels of the spinal cord and collected in sterile PBS (137 mM NaCl, 2.7 mM KCl, 10 mM NaH₂PO₄, pH adjusted to 7.4 with NaOH) at 4 °C. Ganglia were incubated in PBS containing 2 mg ml⁻¹ collagenase enzyme (type I; Worthington, Lakewood, NJ, USA) for 30 minutes with gentle shaking at 37 °C. For further details regarding the isolation and culturing of the cells see (Braun et al., 2015). All experimental procedures using animals were conducted in accordance with the Guide for the Care and Use of Laboratory Animals as adopted by the NIH, local state laws and institutional regulations. All animal experiments were approved by the Animal Care and Ethics Committee of Semmelweis University (approval ID: XIV-I-001/2154-4/2012).

MOL #115626

Two-electrode voltage clamp and patch clamp measurements

Two-electrode voltage clamp experiments were performed 1-3 days after the microinjection of cRNA into *Xenopus* oocytes, as previously described (Czirjak et al., 2004). For each channel type the oocytes contributing to the n number (the exact n number is indicated in the text or on the Figures) were derived from at least two, but usually three separate frogs. The holding potential was 0 mV. Background potassium currents were measured at the end of 300 ms-long voltage steps to -100 mV applied every 4 s. Low potassium recording solution contained (in mM): NaCl 95.4, KCl 2, CaCl₂ 1.8, HEPES 5 (pH 7.5, adjusted by NaOH). The high potassium solution contained 80 mM K⁺ (78 mM NaCl of the low potassium solution was replaced with KCl). For measurement of TREK-1, TREK-2 and TRAAK currents the high potassium solution contained 40 mM K⁺. Solutions were applied to the oocytes using a gravity-driven perfusion system. Experiments were performed at room temperature (21 °C). Data were analyzed by pCLAMP 10 software (Molecular Devices, Sunnyvale, CA, USA).

Whole-cell patch clamp experiments in the voltage clamp configuration were performed as described previously (Lengyel et al., 2016). The resting membrane potential was recorded in the current clamp mode with no current injection (I=0 mode). The rheobase was determined by injecting depolarizing current (in 100 pA increments, up to 1500 pA) for 1 second every 4 seconds. Isolated DRG neurons were used for experiments 1-2 days after isolation. For the current-clamp study of DRG neurons, only cells with a membrane potential between -45 and -70 mV were accepted, as described in previous studies (Petruska et al., 2000). Because the focus of this study was to examine the effects of our new cloxyquin analogues on the electrophysiological parameters of isolated DRG neurons, no other selection criteria were used. Cut-off frequency of the eight-pole Bessel filter was adjusted to 200 Hz, data were acquired at 1 kHz. Pipette solution contained (in

MOL #115626

mM): 140 KCl, 3 MgCl₂, 0.05 EGTA, 1 Na₂-ATP, 0.1 Na₂-GTP and 10 HEPES. Low potassium solution contained (in mM): 140 NaCl, 3.6 KCl, 0.5 MgCl₂, 2 CaCl₂, 11 glucose and 10 HEPES. The high potassium solution contained 30 mM KCl (26.4 mM NaCl of the low potassium solution was replaced with KCl). The pH of the bath solutions were adjusted to 7.4 with NaOH. Experiments were performed at room temperature (21 °C). Data were analyzed by pCLAMP 10.7 software (Molecular Devices, Sunnyvale, CA, USA).

Data and statistical analysis

Results are expressed as means±S.D. Normalized concentration-response curves were fitted with the following modified Hill equation: $\alpha \times c^n / [c^n + K_{1/2}^n] + 1$, where c is the concentration; $K_{1/2}$ is the concentration at which half-maximal stimulation occurs; n is the Hill coefficient; and α is the effect of the treatment. Normality of the data were estimated using the Shapiro-Wilk test. If the Shapiro-Wilk test showed a significant difference between the examined groups, statistical significance was determined using the Mann-Whitney U test. Otherwise, statistical significance was determined with Student's t-test or Fisher's ANOVA followed by Tukey's post hoc test for multiple groups. Results were considered to be statistically significant at $p < 0.05$. The difference in sample sizes between different groups is a consequence of differing number of cells suitable for experimentation; sample sizes were not modified after obtaining initial results. The determined p values are descriptive and not the result of testing prespecified hypotheses. Curve fitting was done using SigmaPlot10 (Build 10.0.0.54, SyStat Software, San Jose, CA, USA). Statistical calculations were done using Statistica (version 13.2, Dell Inc., Tulsa, OK, USA).

Materials

MOL #115626

Chemicals of analytical grade were purchased from Sigma (St. Louis, MO, USA), Fluka (Milwaukee, WI, USA) and Merck (Whitehouse Station, NJ, USA). Enzymes and kits for molecular biology were purchased from Ambion (Austin, TX, USA), Thermo Scientific (Waltham, MA, USA), New England Biolabs (Beverly, MA, USA) or Stratagene (La Jolla, CA, USA). Cloxyquin and ruthenium red (RR) were purchased from Sigma. Ionomycin (calcium salt) was purchased from Enzo Life Sciences (Farmington, NY, USA), dissolved in DMSO as a 5 mM stock solution and stored at -20 °C. Synthesis and chemical analysis of the new compounds described in this study are detailed in the Supporting Information.

MOL #115626

Results

A2764 is a state-dependent inhibitor of mouse TRESK channel

We have synthesized 28 compounds structurally similar to cloxyquin and tested their effects on mouse TRESK (mTRESK) channels expressed in *Xenopus laevis* oocytes using the two-electrode voltage clamp technique. The background K⁺ current was estimated at -100 mV in an extracellular solution containing high K⁺ (80 mM) after the subtraction of the small non-specific leak current measured in 2 mM K⁺. Seven derivatives had stimulatory effect on mTRESK activity similarly to cloxyquin, ten compounds did not influence the K⁺ current, whereas 11 analogues inhibited the channel. Based on our pilot screening of the compounds, the most promising inhibitors (A2764 and A2793) and an activator (A2797) of mTRESK were chosen for in-depth analysis. For the chemical structure of the novel cloxyquin analogues, see Figure 1 (for the chemical structures of the new compounds and details of synthesis and chemical analysis for A2764 and A2793, see the Chemical structures of compounds and the Supplemental Methods sections of the Supporting Information).

The background K⁺ current was inhibited by 42.8±11.5% when A2764 (100 μM) was applied to the oocytes expressing mTRESK (n=7 oocytes, Figure 2A). In addition to the inhibition of the basal current, we also examined the effect of A2764 on the current of activated mTRESK. Ionomycin was used to evoke the elevation of the cytoplasmic [Ca²⁺], which has been previously shown to activate the channel by dephosphorylation via the stimulation of the serine phosphatase, calcineurin (Czirjak et al., 2004). When mTRESK current was increased 7.1±1.8 fold by the pretreatment with ionomycin (0.5 μM), the subsequent application of A2764 (100 μM) strongly inhibited the current (77.8±3.5% inhibition, n=6 oocytes; Figure 2B). The effect of A2764 on mTRESK activated by dephosphorylation was more pronounced than the inhibition of the basal

MOL #115626

current ($p < 0.05$, Mann-Whitney U test, Figure 2C). The concentration-dependence of the channel inhibition was also shifted; while the IC_{50} evoked by A2764 was $11.8 \mu\text{M}$ for the activated channel, the inhibitory potency of the drug was an order of magnitude lower for mTRESK in the resting state (Figure 2D).

A2764 is the most selective modulator among the cloxyquin analogues, tested among a wide range of K_{2P} channels

In order to estimate the selectivity of the novel cloxyquin analogs within the K_{2P} subfamily, we tested them on several mouse K_{2P} channels (at least one member from each subfamily being functional under physiological ionic conditions): TASK-1 ($K_{2P3.1}$), TASK-2 ($K_{2P5.1}$), TASK-3 ($K_{2P9.1}$), TALK-1 ($K_{2P16.1}$), TREK-1 ($K_{2P2.1}$), TREK-2 ($K_{2P10.1}$), TRAAK ($K_{2P4.1}$) and THIK-1 ($K_{2P13.1}$). The channels were expressed in *Xenopus* oocytes and the effect of the compounds was measured by two-electrode voltage clamp ($n=5-7$ oocytes per channel type). Among the three examined cloxyquin analogues, A2764 proved to be the most selective agent; it inhibited the current of TRESK under resting conditions and in the activated state by $42.8 \pm 11.5\%$ ($n=7$) and $77.8 \pm 3.5\%$ ($n=6$), respectively (Figure 3). TREK-1 and TALK-1 currents were reduced only by about 20%, while the other channels were even less affected. The difference in the degree of inhibition between TRESK (both in the resting and in the activated state) and all the examined K_{2P} channels was statistically significant.

The efficiency of the other tested inhibitory analogue (A2793), was higher than that of A2764. At $100 \mu\text{M}$ concentration A2793 inhibited the unstimulated channel by $43.0 \pm 8.9\%$ ($n=5$) while after ionomycin activation the reduction of the TRESK current was $85.5 \pm 2.9\%$ ($n=5$), it was

MOL #115626

practically reduced to the non-activated level, Figure (4A and B). The concentration-response relationship was also determined for both the activated and the basal mTRESK current (Figure 4D). The activated channel was inhibited with an IC_{50} of 6.8 μ M while the inhibitory potency of the compound was more than an order of magnitude smaller in the case of TRESK at basal activity. The specificity of A2793 showed a strikingly different pattern from A2764; it inhibited TASK-1 by $53.4 \pm 13.5\%$ ($n=5$), while all the other channels were influenced by less than 20%. (Figure 4C). These properties may have advantage under experimental conditions when the presence of TASK-1 can be excluded. This was not the case in our studies on native DRG cells, accordingly, we used A2764 in our subsequent experiments.

The chemical structure of the activator analogue (A2797) differed in the aromatic ring from cloxyquin. Its potency was not favourable compared to cloxyquin, it activated TRESK to a similar degree ($437.6 \pm 139.8\%$ of control, $n=9$ oocytes) as the parent compound. Unlike cloxyquin, it activated other K_{2P} channels (TREK-2, TASK-2 and TRAAK) in addition to TRESK; details of these data are available in the Supporting Material (Supplementary Figure 1).

A2764 inhibits the background K^+ currents in DRG neurons

In order to examine the TRESK current in native cells by the application of A2764, we isolated DRG neurons and performed whole-cell patch clamp recordings. Since the functional state of TRESK in cell culture may vary depending on inhibitory kinases and the calcium homeostasis of the neuron, we uniformly induced calcineurin-dependent TRESK dephosphorylation by adding 0.5 μ M ionomycin to our recording solutions before the application of A2764. In addition to the inhibitory effect of A2764 (100 μ M), the sensitivity of the currents to ruthenium red (RR, 30 μ M) was also examined. It is well established that TREK-2, TRAAK and TASK-3 K_{2P} channels are

MOL #115626

inhibited by RR, and TREK-2 and TRAAK were previously reported to be expressed in large subpopulations of DRG neurons.

We applied the two inhibitors (A2764 and RR) into the bath solution successively. A recording from a representative, A2764-sensitive DRG neuron is shown in Figure 5A. The sensitivity of the background current of the examined individual cells to A2764 and RR is presented on a scatter plot; six of the examined ten cells showed substantial A2764-sensitivity (above 40%) while in the other four cells the degree of inhibition was below 20% (Figure 5B). At the same time, we observed a significant negative correlation ($r=-0.9499$, $p<10^{-4}$, Pearson's correlation coefficient) between the amplitudes of A2764- and RR-sensitive current components (see Figure 5B). The current remaining after the elimination of the A2764-sensitive component was substantially reduced by RR (the residual current was $16\pm 9.2\%$), suggesting that the A2764-sensitive (TRESK) and RR-inhibited (most probably TREK-2 and TRAAK) currents were mainly responsible for the background K^+ conductance in the majority of DRG neurons of the examined unselected population.

To validate the assumption that the A2764-sensitive current component of these native cells was indeed TRESK current, we also performed whole cell patch-clamp experiments in the DRG neurons from TRESK knockout mice under identical conditions. As shown on a representative recording in Figure 5C, the application of A2764 (100 μ M) had no effect, but RR substantially inhibited the background K^+ current in this neuron. As apparent on the scatter plot in Figure 5D, A2764 (100 μ M) did not influence the background K^+ current of the DRG neurons derived from the TRESK knockout animals (the average effect on the K^+ current was marginal, $6.5\pm 15.8\%$ inhibition, $n=8$). This was significantly different from the substantial inhibition of the current in the wild type cells ($43.0\pm 29.7\%$, $n=10$, $p<0.05$, Mann-Whitney U test). This result indicates that

MOL #115626

the A2764-sensitive component corresponds to TRESK current, and A2764 is suitable for the investigation of the channel in native cells.

A2764 increases the excitability of DRG neurons

The effect of A2764 on the resting membrane potential and excitability of wild type and TRESK knockout DRG neurons was determined by using the current clamp technique. In the case of the wild type DRG neurons, application of A2764 (100 μ M, in low K^+ recording solution) depolarized the membrane potential by 6.6 ± 5.1 mV, from -57.3 ± 8.5 mV to -50.7 ± 12.5 mV ($p < 0.05$, paired *t*-test, $n=15$, for representative recording see Figure 6A, middle panel). In TRESK knockout DRG neurons, the application of A2764 did not change the resting membrane potential (-55.8 ± 7.3 mV vs. -55.0 ± 7.6 mV, before and after A2764, respectively, $n=13$, for representative recording see Figure 6B, middle panel). The effect of A2764 on the membrane potential was significantly different between the wild type and the knockout animals ($p < 0.05$, *t*-test, Figure 7A), indicating that the depolarization by A2764 was mediated by the inhibition of TRESK.

We also investigated the effect of A2764 application on the excitability of DRG neurons. The rheobase of DRG neurons before and after the application of A2764 (100 μ M) was determined by the injection of depolarizing current impulses of gradually increasing amplitude. The minimum amplitude of current injection necessary for the generation of action potential was reduced after the application of A2764 in most neurons (for representative recording see Figure 6A left and right panels). The reduction of the rheobase was statistically significant (control rheobase: 500 ± 223 pA, $n=6$, A2764 rheobase: 350 ± 160 pA, $n=6$, $p < 0.05$, paired *t*-test, Figure 7B left panel). In sharp contrast, the rheobase of TRESK-deficient DRG neurons was not influenced by A2764 (for representative recording, see Figure 6B left and right panels). The rheobase was 320 ± 130 pA ($n=5$)

MOL #115626

before, and 360 ± 134 pA ($n=5$) after the application of the cloxyquin derivative, respectively (Figure 7B, right panel).

These data consistently indicate that the enhanced excitability induced by A2764 relied on the inhibition of TRESK channel, which is a major determinant of action potential generation in dorsal root ganglionic neurons.

MOL #115626

Discussion

K_{2P} channels are expressed in a wide variety of cell types, where they play a major role in the determination of the resting membrane potential and in the regulation of cellular excitability (for review, see (Enyedi and Czirjak, 2010) and (Feliciangeli et al., 2015)). In comparison with the other K_{2P} channel subunits, the expression pattern of TRESK is more restricted. The channel is abundantly and specifically expressed in the primary sensory neurons of the dorsal root and trigeminal ganglia. In accordance with this localization, TRESK has been implicated in the modulation of both physiological and pathophysiological nociception (for recent reviews, see (Mathie and Veale, 2015) and (Enyedi and Czirjak, 2015)). Important functional data highlighting TRESK as a regulator of cellular excitability in primary sensory neurons was obtained by either eliminating TRESK (by transient knockdown or by using knockout animal strains), transiently overexpressing the channel, or by using pharmacological modulators of channel activity ((Dobler et al., 2007; Guo and Cao, 2014; Tulleuda et al., 2011)). An accumulating body of evidence also indicates that TRESK current alterations may contribute to the pathological mechanism of neuropathic, migraine, and cancer pain (Lafreniere et al., 2010; Tulleuda et al., 2011; Yang et al., 2018).

The examination of the role of TRESK in primary sensory neurons is impeded by the lack of specific modulators. Several pharmacological agents, including inorganic modulators as zinc or mercuric ion (Czirjak and Enyedi, 2006), the natural compounds hydroxy- α -sanshool from Szechuan peppers (Bautista et al., 2008) and aristolochic acid (AristA) from *Aristolochiaceae* plants (Veale and Mathie, 2016), approved medicines as lamotrigine or verapamil (Kang et al., 2008; Park et al., 2018), and also the insecticide pyrethroids (Castellanos et al., 2017) were demonstrated to inhibit TRESK current.

MOL #115626

Although these agents are known to have other pharmacological targets in addition to TRESK, and in most cases they were also shown to influence the activity of other K_{2P} channels, they provided the first options to experimentally manipulate TRESK current of sensory neurons. As another tool to achieve this goal, cloxyquin, an antiameobic drug, was identified as a TRESK activator in a high-throughput screening (Wright et al., 2013). We have recently shown that cloxyquin is selective for TRESK in the K_{2P} family and can activate the background K^+ current in mouse DRG neurons (Lengyel et al., 2017). Nevertheless, high concentration of cloxyquin (in the 50-100 μ M range) was required for TRESK activation. Therefore, we have synthesized 28 chemically modified analogues of cloxyquin to see if we can find more potent activators of TRESK. After a pilot screening on mouse TRESK channel expressed in *Xenopus* oocytes, it became apparent that the potency of these derivatives for TRESK activation was not increased by the chemical modification, however, their pharmacological profile has been changed substantially. Some of the analogues turned out to be inhibitors of TRESK, in sharp contrast to the activator parent compound cloxyquin. We have chosen the most potent analogues (one activator and two inhibitors) for further analysis.

The A2797 compound activated mTRESK current about four-fold at 100 μ M concentration. This degree of activation was similar to the previously reported effect of cloxyquin (Lengyel et al., 2017). However, as opposed to the relative selectivity of cloxyquin for TRESK in the K_{2P} family, A2797 also activated TREK-2, TASK-2 and TRAAK channels. This indicates that modification of the aromatic ring of cloxyquin may substantially influence the effect of the compound on various members of the background potassium channel family.

Modification of the hydroxyl sidechain in the chlorinated hydroxyquinoline parent molecule resulted in inhibitory derivatives. We have recently reported that cloxyquin showed state-dependence in its effect; it was only able to activate TRESK in the resting state, but not when the

MOL #115626

channel was activated by the Ca^{2+} /calcineurin pathway (Lengyel et al., 2017). Intrigued by the possibility that our inhibitors also show state-dependent effects, we determined the degree of inhibition by A2793 for both the resting mTRESK and the channels preactivated by application of the calcium ionophore ionomycin. Interestingly, the state-dependence of the effect of A2793 proved to be the mirror image of that of cloxyquin. The inhibition by the compound was definitely more pronounced when TRESK current was stimulated with ionomycin before the application of A2793 than under the resting conditions of the channel.

The effect of A2793 was also tested on the other $\text{K}_{2\text{P}}$ channels in addition to TRESK. It proved to be an efficient inhibitor of TASK-1, which was also reported to be expressed in some primary sensory neurons (Cooper et al., 2004). The effect on TASK-1 may limit the potential usage of A2793 to selectively inhibit TRESK in the native cells coexpressing these two specific $\text{K}_{2\text{P}}$ channels. However, A2793 may be considered as a tool to discriminate between the resting and activated channels in heterologous expression systems, and to block TRESK activated by calcineurin in the native cells which do not express TASK-1.

The other cloxyquin derivative A2764 was also found to exert state-dependent effect. Similarly to A2793, inhibition by this compound was larger in the case of the activated TRESK than at the resting channel. The concentration-response relationship between A2764 and mTRESK current was also shifted to the left by the calcineurin-dependent dephosphorylation of the channel induced by the application of the Ca^{2+} ionophore ionomycin.

We have also determined the effect of A2764 on the other $\text{K}_{2\text{P}}$ channels expressed in *Xenopus* oocytes. The substantial inhibition of TASK-1 (by A2793) was missing from the profile

MOL #115626

of A2764, thus A2764 showed much better overall selectivity for TRESK among the K_{2P} channels than the other inhibitor. The degree of inhibition of the most affected other K_{2P} channels (TREK-1 and TALK-1) was moderate ($21.0\pm 9.7\%$ and $22.4\pm 10.3\%$, respectively), compared with the robust inhibition of dephosphorylated TRESK ($77.8\pm 3.5\%$), suggesting that A2764 could be used as a selective inhibitor of TRESK in isolated cells *in vitro*.

In order to test the hypothesis that A2764 can be applied to inhibit TRESK and thus determine the contribution of the channel to the ensemble background K^+ current in native cells, we have performed whole-cell patch clamp experiments in DRG neurons from both wild-type and TRESK knockout mice. Based on previous single channel and immunocytochemical results, in the DRG neurons primarily the expression of two major K_{2P} channels, TRESK and TREK-2 was expected (Acosta et al., 2014; Kang and Kim, 2006). To estimate the contribution of these channels to the background K^+ current by a further independent method, we determined the degree of inhibition by A2764 and ruthenium red (RR). We have previously described that RR inhibits background K^+ currents in DRG neurons (Braun et al., 2015). The molecular correlates of the RR-sensitive K^+ current may be TREK-2, TASK-3 or TRAAK homodimers, or heterodimers of the TREK subfamily (Blin et al., 2016; Braun et al., 2015; Lengyel et al., 2016). We found that in neurons derived from wild type animals, A2764 strongly inhibited the background K^+ current in a subset of DRG neurons. However, this subset of A2764-sensitive neurons was completely missing from the DRG neurons prepared from TRESK knockout animals. Based on these results from the wild-type and TRESK knockout DRG neurons, we propose that A2764 is a useful selective inhibitor of TRESK.

In order to determine the contribution of TRESK and the RR-sensitive channels to the background K^+ current, the sensitivity of the current to the two inhibitors was determined in the

MOL #115626

same DRG neurons. We found an inverse correlation between the amplitude of the A2764-sensitive and RR-sensitive currents, indicating that the cells where TRESK is the major determinant of the background K^+ current express relatively less RR-sensitive K_{2P} channels and vice versa. In the DRG neurons analyzed, around 80% of the background K^+ current was sensitive to the combination of A2764 and RR. We have thus shown for the first time using whole-cell patch clamp that TRESK and various RR-sensitive K_{2P} subunits are the major determinants of the background K^+ current of isolated mouse DRG neurons. The application of A2764 offers a viable alternative of the previous methods for the investigation of TRESK and its regulation in the different functionally important subpopulations of primary sensory neurons.

In good accordance with the efficient inhibition of TRESK current by A2764, the application of this inhibitor also depolarized DRG neurons, and appreciably increased their excitability *in vitro*, as indicated by the decreased rheobase in current clamp experiments. Since these effects and also the inhibition of the background K^+ current was completely absent in the neurons isolated from the knockout animals, we concluded that the current component blocked by A2764 corresponds to TRESK. We propose that cloxyquin and A2764 can be used to modulate the activity of TRESK channels in native cells, and the TRESK knockout mouse line can serve as a reliable negative control in these experiments. We hope that with this combined genetic and pharmacological approach the functional relevance of the enigmatic TRESK channel can be further elucidated.

MOL #115626

Author Contributions

Participated in research design: Bálint-Polonka, Czirják, Enyedi, Hegedűs and Lengyel.

Conducted experiments: Bálint-Polonka, Bozsaki, Dobolyi, Erdélyi, Király, Lengyel and Pergel.

Contributed new reagents or analytic tools: Erdélyi and Mátyus.

Performed data analysis: Bozsaki, Czirják, Hegedűs, Király, Lengyel, Mátyus and Pergel.

Wrote or contributed to the writing of the manuscript: Bozsaki, Czirják, Dobolyi, Dux, Enyedi, Erdélyi, Hegedűs, Király, Lengyel, Mátyus and Pergel.

Acknowledgements

The skillful technical assistance of Irén Veres is acknowledged.

Conflict of interest

None declared.

References

- Acosta C, Djouhri L, Watkins R, Berry C, Bromage K and Lawson SN (2014) TREK2 expressed selectively in IB4-binding C-fiber nociceptors hyperpolarizes their membrane potentials and limits spontaneous pain. *J Neurosci* **34**(4): 1494-1509.
- Bautista DM, Sigal YM, Milstein AD, Garrison JL, Zorn JA, Tsuruda PR, Nicoll RA and Julius D (2008) Pungent agents from Szechuan peppers excite sensory neurons by inhibiting two-pore potassium channels. *Nat Neurosci* **11**(7): 772-779.
- Blin S, Ben Soussia I, Kim EJ, Brau F, Kang D, Lesage F and Bichet D (2016) Mixing and matching TREK/TRAAK subunits generate heterodimeric K2P channels with unique properties. *Proc Natl Acad Sci U S A* **113**(15): 4200-4205.
- Braun G, Lengyel M, Enyedi P and Czirjak G (2015) Differential sensitivity of TREK-1, TREK-2 and TRAAK background potassium channels to the polycationic dye ruthenium red. *British Journal of Pharmacology* **172**(7): 1728-1738.
- Castellanos A, Andres A, Bernal L, Callejo G, Comes N, Gual A, Giblin JP, Roza C and Gasull X (2017) Pyrethroids inhibit K2P channels and activate sensory neurons: basis of insecticide-induced paraesthesias. *PAIN Articles in Press*.
- Cooper BY, Johnson RD and Rau KK (2004) Characterization and function of TWIK-related acid sensing K⁺ channels in a rat nociceptive cell. *Neuroscience* **129**(1): 209-224.

MOL #115626

- Czirjak G and Enyedi P (2002) Formation of functional heterodimers between the TASK-1 and TASK-3 two-pore domain potassium channel subunits. *J Biol Chem* **277**(7): 5426-5432.
- Czirjak G and Enyedi P (2006) Zinc and mercuric ions distinguish TRESK from the other two-pore-domain K⁺ channels. *Mol Pharmacol* **69**(3): 1024-1032.
- Czirjak G, Toth ZE and Enyedi P (2004) The two-pore domain K⁺ channel, TRESK, is activated by the cytoplasmic calcium signal through calcineurin. *J Biol Chem* **279**(18): 18550-18558.
- Dobler T, Springauf A, Tovornik S, Weber M, Schmitt A, Sedlmeier R, Wischmeyer E and Doring F (2007) TRESK two-pore-domain K⁺ channels constitute a significant component of background potassium currents in murine dorsal root ganglion neurones. *J Physiol* **585**(Pt 3): 867-879.
- Enyedi P and Czirjak G (2010) Molecular background of leak K⁺ currents: two-pore domain potassium channels. *Physiol Rev* **90**(2): 559-605.
- Enyedi P and Czirjak G (2015) Properties, regulation, pharmacology, and functions of the K(2)p channel, TRESK. *Pflugers Arch* **467**(5): 945-958.
- Feliciangeli S, Chatelain FC, Bichet D and Lesage F (2015) The family of K2P channels: salient structural and functional properties. *J Physiol* **593**(12): 2587-2603.
- Guo Z and Cao YQ (2014) Over-expression of TRESK K(+) channels reduces the excitability of trigeminal ganglion nociceptors. *PLoS One* **9**(1): e87029.
- Kang D and Kim D (2006) TREK-2 (K2P10.1) and TRESK (K2P18.1) are major background K⁺ channels in dorsal root ganglion neurons. *Am J Physiol Cell Physiol* **291**(1): C138-146.
- Kang D, Kim GT, Kim EJ, La JH, Lee JS, Lee ES, Park JY, Hong SG and Han J (2008) Lamotrigine inhibits TRESK regulated by G-protein coupled receptor agonists. *Biochem Biophys Res Commun* **367**(3): 609-615.
- Lafreniere RG, Cader MZ, Poulin JF, Andres-Enguix I, Simoneau M, Gupta N, Boisvert K, Lafreniere F, McLaughlan S, Dube MP, Marcinkiewicz MM, Ramagopalan S, Ansorge O, Brais B, Sequeiros J, Pereira-Monteiro JM, Griffiths LR, Tucker SJ, Ebers G and Rouleau GA (2010) A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura. *Nat Med* **16**(10): 1157-1160.
- Lengyel M, Czirjak G and Enyedi P (2016) Formation of Functional Heterodimers by TREK-1 and TREK-2 Two-pore Domain Potassium Channel Subunits. *J Biol Chem* **291**(26): 13649-13661.
- Lengyel M, Dobolyi A, Czirjak G and Enyedi P (2017) Selective and state-dependent activation of TRESK (K2P 18.1) background potassium channel by cloxyquin. *Br J Pharmacol*.
- Mathie A and Veale EL (2015) Two-pore domain potassium channels: potential therapeutic targets for the treatment of pain. *Pflugers Arch* **467**(5): 931-943.
- Park H, Kim EJ, Ryu JH, Lee DK, Hong SG, Han J, Han J and Kang D (2018) Verapamil Inhibits TRESK (K2P18.1) Current in Trigeminal Ganglion Neurons Independently of the Blockade of Ca(2+) Influx. *Int J Mol Sci* **19**(7).
- Petruska JC, Napaporn J, Johnson RD, Gu JG and Cooper BY (2000) Subclassified acutely dissociated cells of rat DRG: histochemistry and patterns of capsaicin-, proton-, and ATP-activated currents. *J Neurophysiol* **84**(5): 2365-2379.
- Sanjana NE, Cong L, Zhou Y, Cunniff MM, Feng G and Zhang F (2012) A transcription activator-like effector toolbox for genome engineering. *Nat Protoc* **7**(1): 171-192.
- Sano Y, Inamura K, Miyake A, Mochizuki S, Kitada C, Yokoi H, Nozawa K, Okada H, Matsushime H and Furuichi K (2003) A novel two-pore domain K⁺ channel, TRESK, is localized in the spinal cord. *J Biol Chem* **278**(30): 27406-27412.
- Tulleuda A, Cokic B, Callejo G, Saiani B, Serra J and Gasull X (2011) TRESK channel contribution to nociceptive sensory neurons excitability: modulation by nerve injury. *Mol Pain* **7**: 30.
- Veale EL and Mathie A (2016) Aristolochic acid, a plant extract used in the treatment of pain and linked to Balkan Endemic Nephropathy, is a regulator of K2P channels. *Br J Pharmacol*.

MOL #115626

- Wright PD, Weir G, Cartland J, Tickle D, Kettleborough C, Cader MZ and Jerman J (2013) Cloxyquin (5-chloroquinolin-8-ol) is an activator of the two-pore domain potassium channel TRESK. *Biochemical and Biophysical Research Communications* **441**(2): 463-468.
- Yamamoto Y, Hatakeyama T and Taniguchi K (2009) Immunohistochemical colocalization of TREK-1, TREK-2 and TRAAK with TRP channels in the trigeminal ganglion cells. *Neurosci Lett* **454**(2): 129-133.
- Yang Y, Li S, Jin ZR, Jing HB, Zhao HY, Liu BH, Liang YJ, Liu LY, Cai J, Wan Y and Xing GG (2018) Decreased abundance of TRESK two-pore domain potassium channels in sensory neurons underlies the pain associated with bone metastasis. *Sci Signal* **11**(552).
- Yoo S, Liu J, Sabbadini M, Au P, Xie GX and Yost CS (2009) Regional expression of the anesthetic-activated potassium channel TRESK in the rat nervous system. *Neurosci Lett* **465**(1): 79-84.

MOL #115626

Footnotes:

Funding acknowledgement: This work was supported by the Hungarian Research Fund [NKFIH K-127988] and the Higher Education Institutional Excellence Program of the Ministry of Human Capacities in Hungary, within the framework of the Molecular Biology thematic program of the Semmelweis University. M.L. was supported by the New National Excellence Program of the Ministry of Human Capacities [ÚNKP-18-3-III-SE-43] and [EFOP-3.6.3-VEKOP-16-2017-00009, program name: “Az orvos-, egészségtudományi- és gyógyszerész képzés tudományos műhelyeinek fejlesztése”]

MOL #115626

Figure legends

Figure 1. Chemical structures of novel cloxyquin derivatives.

Chemical structures of the new cloxyquin analogues reported in this study (A2764, A2793 and A2797). The structure of the parent compound is shown for comparison.

Figure 2. A2764 is a state-dependent inhibitor of mouse TRESK (mTRESK).

A, Normalized currents of oocytes expressing mTRESK, measured by the two-electrode voltage clamp technique. Currents were measured at the end of 300-ms voltage steps to -100 mV applied every 4 s from a holding potential of 0 mV. The extracellular K⁺ concentration was increased from 2 to 80 mM as indicated by the bars above the graph. Oocytes were challenged with A2764 (100 μM, see the horizontal bar). Currents were normalized to the value measured in 80 mM K⁺ before the application of the drug. The current measured in 80 mM K⁺ before application of A2764 was 2.9±1.5 μA. Data are plotted as mean±S.D.

B, The effect of A2764 on the activated mTRESK channels was determined under the same experimental conditions as in panel A. The current measured in 80 mM K⁺ before application of ionomycin was 1.5±0.8 μA. TRESK current was activated by the application of 0.5 μM ionomycin (by 7.1±1.8 fold), which was followed by the addition of A2764 (100 μM) to the bath solution (the timing of the changes of K⁺ concentration and drug application are marked by horizontal bars above the graph). Currents were normalized to the value measured after ionomycin stimulation, before the application of A2764.

C, The data from Figures 2A and 2B has been summarized as a column graph. Mean inhibitions of the resting and activated TRESK currents are plotted, and the number of oocytes in

MOL #115626

each group is given in parentheses. The difference in the degree of inhibition was statistically significant ($p < 0.05$, Mann-Whitney-U test).

D, Concentration-response relationship of A2764 and mTRESK current. The inhibitory effect of different concentrations of A2764 (in a range from 1 to 100 μM) on basal (white circles) and activated (black diamonds) TRESK current are plotted. Each data point represents the average of 5 to 11 oocytes (the exact number is indicated in parentheses). The data points were fitted with a modified Hill equation (see *Methods*).

Figure 3. A2764 is a selective inhibitor of mTRESK.

Mouse $\text{K}_{2\text{P}}$ channels were expressed in *Xenopus* oocytes. The effect of A2764 (100 μM) on the inward current in 80 mM extracellular K^+ (or 40 mM in the case of TREK-1, TREK-2 and TRAAK) was determined in 5-7 oocytes per channel type as in Figure 2A. As a comparison, the data points corresponding to the inhibition of basal or activated TRESK current from Figure 2 are also plotted. Mean inhibition for each channel type is plotted as a column graph. The error bars represent S.D.

Figure 4. A2793 is an inhibitor of mTRESK and mTASK-1.

A, Mouse TRESK was expressed in *Xenopus* oocytes. The oocytes were challenged with A2793 (100 μM). The current measured in 80 mM K^+ before application of A2793 was 2.6 ± 0.6 μA . Inhibition by A2793 was determined and presented as described in Figure 2A.

B, The effect of A2793 on the activated mTRESK current was determined under the same experimental conditions detailed in Figure 2B. The current measured in 80 mM K^+ before application of ionomycin was 1.7 ± 0.7 μA . Ionomycin activated the current by 6.7 ± 2.0 fold.

MOL #115626

C, To determine the selectivity of A2793, mouse K_{2P} channels were expressed in *Xenopus* oocytes. The effect of A2793 on the inward current in 80 mM extracellular K^+ (or 40 mM in the case of TREK-1, TREK-2 and TRAAK) was determined in 5 oocytes per channel type as in Figure 3. As a comparison, the data points corresponding to the inhibition of TRESK current from panels A and B are also plotted. Data are plotted as mean+S.D.

D, Concentration-response relationship of A2793 and mTRESK current. The inhibitory effect of different concentrations of A2793 (in a range from 1 to 100 μ M) on basal (white circles) and activated (black diamonds) TRESK current are plotted. Each data point represents the average of 5 oocytes. The data points were fitted with a modified Hill equation (see *Methods*).

Figure 5. A2764 inhibits the background K^+ current in DRG neurons.

DRG neurons isolated from either wild-type or TRESK knockout mice were used for whole-cell patch clamp experiments. Inward currents were measured in 3.6 mM or 30 mM extracellular K^+ at the end of 200 ms voltage steps to -100 mV from a holding potential of -80 mV. Changes in extracellular K^+ concentration and application of A2764 (100 μ M) and RR (30 μ M) are marked above the graphs. To convert TRESK channels into their active state, the bath solution contained 0.5 μ M ionomycin.

A, A representative recording is shown from a wild type, A2764-sensitive DRG neuron.

B, The effect of A2764 and RR on the background K^+ current was measured in ten DRG neurons. The degrees of inhibition by A2764 and RR were plotted against each other. Linear regression was performed, the regression line was plotted in addition to the data points (the corresponding equation and R value are also shown).

C, A representative recording is shown from a TRESK knockout DRG neuron.

MOL #115626

D, The effect of A2764 and RR on the background K^+ current was measured in eight DRG neurons isolated from TRESK knockout mice. The degrees of inhibition by A2764 and RR were plotted against each other.

Figure 6. A2764 increases the excitability of DRG neurons by inhibiting TRESK.

DRG neurons isolated from either wild-type or TRESK knockout mice were used for current clamp experiments. The rheobase was determined by injecting depolarizing current impulses in 100 pA increments before and after application of A2764 (100 μ M). The effect of A2764 (100 μ M) was determined without any current injection (I=0 mode).

A, Representative recordings are shown from a wild type DRG neuron. Left and right panel: The first traces where current injection resulted in an action potential before and after application of A2764 are plotted.

Middle panel: Application of A2764 leads to depolarization of the resting membrane potential. Application of the drug is marked by the horizontal line above the recording.

B, Representative recordings are shown from a TRESK knockout DRG neuron. Left and right panel: The first traces where current injection resulted in an action potential before and after application of A2764 are plotted.

Middle panel: Application of A2764 has no effect on the resting membrane potential. Application of the drug is marked by the horizontal line above the recording.

MOL #115626

Figure 7. Summary of the effect of A2764 on wild type and TRESK knockout DRG neurons.

A, The resting membrane potential of 15 wild type (left panel) and 13 TRESK knockout (right panel) DRG neurons was measured before (Control) and after A2764 (100 μ M) application. Data points corresponding to one neuron are connected with a straight line.

B, The rheobase of 6 wild type (left panel) and 5 TRESK knockout (right panel) DRG neurons was measured before (Control) and after A2764 (100 μ M) application. Data points corresponding to one neuron are connected with a straight line.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6





Figure 7



Supporting Information for Molecular Pharmacology Manuscript #115626

Title: Chemically Modified Derivatives of the Activator Compound Cloxyquin Exert Inhibitory Effect on TRESK (K_{2P18.1}) Background Potassium Channel

Author information: Miklós Lengyel¹, Ferenc Erdélyi², Enikő Pergel¹, Ágnes Bálint-Polonka^{3,*}, Alice Dobolyi¹, Péter Bozsaki¹, Mária Dux⁴, Kornél Király⁵, Tamás Hegedűs⁶, Gábor Czirják¹, Péter Mátyus^{3,**} and Péter Enyedi¹

From the Department of Physiology, Faculty of Medicine, Semmelweis University, Budapest, Hungary

Affiliations:

1: Department of Physiology, Faculty of Medicine, Semmelweis University, Budapest, Hungary

2: Gene Technology Division, Institute of Experimental Medicine – HAS, H-1083 Budapest, Hungary

3: Department of Organic Chemistry, Faculty of Pharmacy, Semmelweis University

4: Department of Physiology, Faculty of Medicine, University of Szeged, Szeged, Hungary

5: Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Semmelweis University


6: Department of Biophysics and Radiation Biology, Faculty of Medicine, Semmelweis University

*: Present address: Hungarian Accreditation Committee, 1013 Budapest, Krisztina krt. 39


** : Present address: Faculty of Health and Public Services, Semmelweis University

Chemical structure of compounds analysed in this study:


Inhibitory compounds (Compounds of which 100 μ M inhibited TRESK current by at least 20%):




A2751




A2752




A2754




A2755




A2764




A2793




A2795




A2799



A2800




A2801




A2802


Stimulatory compounds: (Compounds of which 100 μ M activated TRESK current by at least 50%):




A2753




A2759




A2760




A2797



A2798




A2803




A2804


Compounds with no effect (Current after application of 100 μ M compound was 90 to 140% of the control)




A2794




A1092




A1093




A1095




A1518




A1527




A2805



A2806



A2807



4-chlorophenol

Supplemental Methods

Synthesis and analysis of cloxyquin analogues which were analyzed in detail in this study.

Compound 4-chloronaphtalen-1-ol (A2797) was commercially available (Sigma). All reagents and solvents (99 % purity) were purchased from commercial sources and used without further purification. Compounds A2764 and A2793 were synthesized in the Department of Organic Chemistry (Simmelweis University) as follows.

Cloxyquin (500 mg, 2.784 mmol) was dissolved in *N,N*-dimethylformamide (10 mL) and to the solution, K_2CO_3 (1.15 g, 8.352 mmol for A2764; 770 mg, 5.568 mmol for A2793) was added. The reaction mixture was cooled to 5 °C, then the appropriate alkylating reagent (4.176 mmol), *N*-2-chloroethyl-*N,N*-diethylamine hydrochloride (for A2764) or ethyl bromoacetate (for A2793), was added. The resulting mixture was stirred at 50 °C overnight (for A2793) or at room temperature for 7 hours (for A2764), while monitoring tlc. Then, the reaction mixture was concentrated under reduced pressure, and to the residue water was added (20 mL). It was extracted with ethyl acetate (3×20 mL). The organic phase was dried over $MgSO_4$ and the solvent was evaporated under reduced pressure.

2-((5-Chloroquinolin-8-yl)oxy)-*N,N*-diethylethanamine hydrochloride (A2764)

The oily residue was purified by column chromatography (silica gel, EtOAc-EtOH-25% aq. NH_3 solution 10:3:0.25).

Yellow oil (73%). δ (ppm) 1H NMR (300 MHz, $CDCl_3$): 8.99 (dd, 1H), 8.53 (dd, 1H), 7.54 (dd, 1H), 7.53 (d, 1H), 7.02 (d, 1H), 4.31 (t, 2H), 3.11 (t, 2H), 2.69 (q, 4H), 1.10 (t, 6H). δ (ppm) ^{13}C

NMR (CDCl₃): 153.8, 149.7, 140.8, 133.0, 127.1, 126.4, 122.3, 122.1, 108.5, 67.2, 51.4, 47.7, 11.7.

(CAS: 809248-52-0)

2.5 Hydrochloride salt (prepared with HCl in ethanol), hygroscopic, mp: 184-185 °C. δ ¹H NMR (300 MHz, DMSO-*d*₆): 10.76 (s, 1H), 9.14 (d, 1H), 8.88 (d, 1H), 7.98 (dd, 1H), 7.91 (d, 1H), 7.49 (d, 1H), 4.65 (t, 2H), 3.65 (t, 2H), 3.42-3.22 (m, 4H), 1.29 (t, 6H). δ ¹³C NMR (DMSO-*d*₆): 148.3, 128.2, 126.5, 123.8, 122.1, 112.3, 63.8, 49.6, 46.6, 8.45. Elementary analysis calc.: C(%): 48.70, H(%): 5.86, N(%): 7.57, found: C(%): 47.71, H(%): 6.40, N(%): 7.32.

Ethyl ((5-chloroquinolin-8-yl)oxy)acetate (A2793)

The oily residue was crystallized in ethanol and purified by column chromatography (silica gel, hexane-ethyl acetate 4:1).

White powder (82%), mp: 107-108 °C. δ (ppm) ¹H NMR (300 MHz, CDCl₃): 9.01 (dd, 1H), 8.55 (dd, 1H), 7.57 (dd, 1H), 7.52 (d, 1H), 6.91 (d, 1H), 4.96 (s, 2H), 4.28 (q, 2H), 1.28 (t, 3H). δ (ppm) ¹³C NMR (CDCl₃): 168.5, 152.9, 150.0, 140.7, 133.0, 127.2, 126.1, 123.5, 122.5, 109.5, 66.3, 61.5, 14.1. Elementary analysis calc.: C(%): 58.77, H(%): 4.55, N(%): 5.27, found: C(%): 57.68, H(%): 4.73, N(%): 4.93.

CAS: 88349-90-0

Supplementary Figure 1. A2797 is a less-selective activator of mTRESK than cloxyquin.

A, Mouse TRESK was expressed in *Xenopus* oocytes. The effect of A2797 (100 μ M) was determined and presented as described in Figure 2A.

B, Concentration-response relationship of A2797 and mTRESK current. The stimulatory effect of different concentrations of A2797 (in a range from 1 to 100 μ M) on mTRESK current are plotted. Each data point represents the average of 5 to 14 oocytes (the exact number is stated in parentheses). The data points were fitted with a modified Hill equation (see *Methods*). Because of the limited water solubility concentrations higher than 100 μ M could

not be tested although the maximal stimulation was not attained. Accordingly, the degree of activation by 100 μ M A2797 was used in the calculation for the apparent EC_{50} which is therefore underestimated.

C, To determine the selectivity of A2797, mouse K_{2P} channels were expressed in *Xenopus* oocytes. The effect of A2797 on the inward current in 80 mM extracellular K^+ (or 40 mM in the case of TREK-1, TREK-2 and TRAAK) was determined in 5-7 oocytes per channel type (the exact numbers are shown in the columns). As a comparison, the data points corresponding to the activation of TRESK current from panel A are also plotted.

Supplementary Figure 1

